Article
Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma
17 Jan 2020
Abstract excerpt
OBJECTIVE: Although methotrexate (MTX) is commonly used for the treatment of choriocarcinoma, chemoresistance to MTX may occur in a considerable fraction of patients. Further understanding on the mechanisms of MTX resistance would help to develop more effective therapy for choriocarcinoma. METHODS: Quantitative proteomic approach involving TMT labeling and LC-MS/MS was used to identify MTX resistance-related...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
